From Seeking Alpha
Leerink positive on Insmed, sees opportunity for Arikace in NTM • 3:02 PM
Leerink has done some investigating and analyst Joseph Schwartz is now "more bullish on Arikace's ability to generate an approvable portfolio of clinical data."
That's good news for Insmed (INSM +5.2%) shareholders who took a big hit around the first of July after Phase 3 trial results suggested Novartis' Tobi performed better on lung function tests.
Schwartz likes the prospects for Arikace in non-tuberculous mycobacterial (NTM) lung disease, which is where UBS identified an "underappreciated opportunity" back in June.
"The clinical relevance of TARGET's secondary endpoints, and the seriousness of the NTM cases afflicting TARGET's patient population ... could lower the bar for trial success," Schwartz says, referring to an ongoing trial of Arikace in NTM.
Price target reiterated at $22.